My name is Jack Egelund Madsen. I'm the CEO of Diagonal Bio. I'll give an update of the last quarter in connection to release of our Q3 financial report. What we're really happy about is that there's a lot of pressure on the notified bodies, so that we actually already signed on with with BSI. That is British Standards Institution, so it's a notified body that will help the regulatory process. We will have the stage one audit with the BSI on 10th of November. According to the milestones in the prospectus, we expect to have the quality management system fully implemented and in use by the end of the year. It's of course a good achievement on the regulatory pathway, and we are very happy with that. We are very happy about the new lab. Of course, it's very close to the offices that we have here at the Medicon Village. That of course means that we can do a lot more in-house testing than we used to. That will also both, you can say, increase the efficiency. It will be much easier for us to do additional testing. Also we can say we make sure that we anchor the know-how and knowledge within the team. We have been working with the initial industrial design with an external partner. Of course, the output is something that makes us very happy. It's with focus on extreme ease of use, and it will be a small machine that can basically be placed anywhere. We are of course continuing to work on the optimization for manufacturing and scale-up. I think we see PANVIRAL as, you can say the new gold standard of infectious disease testing. Today, you always have to use the PCR if you want high accuracy. For quick testing, you can say it's not really usable. It takes too long. You'll get flu symptoms. You wanna make sure whether it's COVID, what type of COVID mutation, influenza A and B, or just could also be respiratory bacteria. With PANVIRAL, you get the answer within these 10-15 minutes. Otherwise you would have to go through a lot of different testings. Where we see PANVIRAL is not just for COVID testing, but in all type of testing actually. You should imagine that PANVIRAL will be the new gold standard in infectious disease testing and can be used for the Basically any type of infectious disease. As we see it for PANVIRAL, there will be hardly any limitation in where this could be used. It will be a fairly small machine, and it will be able to be placed at basically anywhere. It could be at a pharmacy, it could be at the general practitioners, it could be in emergency rooms, it could be at big sporting events or at the airports. Basically with the size and ease of use, it could be used basically anywhere. You can see that the vision for PANVIRAL is that we will basically come in and take a, of course, a big market share. It will be a global system. Essentially where we see it is that, where everybody would use PCR today as the gold standard, they will be using PANVIRAL instead. That's a pretty ambitious vision, but we are of course also working really hard to actually achieve. I would also like to mention that Kushagr Punyani, one of the co-founders of Diagonal and the tech advisor to the company, received the King Carl Gustaf Award for Newcomer of the Year 2021. We are of course very happy on behalf of Kushagr Punyani. As a final comment, I would like to thank our investors for the trust and support and for taking part in our exciting journey. I look forward to working further towards future milestones and to continue the development of PANVIRAL. Thank you.